Novartis' Kisqali Scores Big Win In Competitive CDK4/6 Space
Executive Summary
Data at ASCO showed a statistically significant overall survival advantage in pre- and perimenopausal women with advanced HR+, HER2- breast cancer, a first for the CDK4/6 class.
You may also be interested in...
Novartis All Smiles After Kisqali OS Success In MONALEESA-2
After the presentation of stellar long-term survival data at ESMO for Kisqali in women with HR+/HER2- advanced breast cancer, Novartis is planning to knock Pfizer's Ibrance off its CDK4/6 inhibitor perch with the help of a head-to-head trial.
Survival Data Boost Lilly & Novartis’s CDK4/6 Assault On Pfizer’s Ibrance In Metastatic Breast Cancer
Pfizer’s dominance of the CDK4/6 inhibitor market will come under renewed pressure as the MONALEESA-3 and MONARCH-2 studies for Novartis’s Kisqali and Lilly’s Verzenio presented at ESMO confirmed their survival benefits in advanced hormone-receptor-positive, HER2-negative breast cancer. The data firmly push the drug class into front-line advanced setting in these patients.
Oncology Market Leaders Maintain Their Upper Hand
Drugs like Ibrance and Lynparza show that in the cancer market, it can be hard for new entrants to catch early standouts.